EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
18 Setembro 2023 - 8:00AM
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed
to developing and commercializing therapeutics to help improve the
lives of patients with serious eye disorders, today announced that
the Company granted non-statutory stock options to new employees as
inducement awards outside the Company’s 2023 Long-Term Incentive
Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up
to an aggregate of 4,000 shares of EyePoint Pharmaceuticals common
stock to two new employees. The stock options were granted on
September 15, 2023. The grants were approved by the Compensation
Committee and made as an inducement material to each employee
entering into employment with EyePoint Pharmaceuticals in
accordance with NASDAQ Listing Rule 5635(c)(4). The option awards
have an exercise price of $10.48 per share, the closing price of
EyePoint Pharmaceuticals’ common stock on September 15, 2023. The
options have a ten-year term and vest over four years, with 25% of
the original number of shares vesting on the first anniversary of
the applicable employee’s date of grant and the remainder vesting
in equal monthly installments over the following three years.
Vesting of the options is subject to the employee’s continued
service with EyePoint Pharmaceuticals through the applicable
vesting dates.
About EyePoint
Pharmaceuticals
EyePoint Pharmaceuticals (Nasdaq: EYPT) is a
company committed to developing and commercializing therapeutics to
help improve the lives of patients with serious eye disorders. The
Company's pipeline leverages its proprietary erodible Durasert E™
technology for sustained intraocular drug delivery including
EYP-1901, an investigational sustained delivery intravitreal
anti-VEGF treatment currently in Phase 2 clinical trials. The
proven Durasert® drug delivery platform has been safely
administered to thousands of patients' eyes across four U.S. FDA
approved products. EyePoint Pharmaceuticals is headquartered in
Watertown, Massachusetts. For more information visit
www.eyepointpharma.com.
For EyePoint Pharmaceuticals:
Investors:Christina TartagliaStern
IRDirect: 212-698-8700christina.tartaglia@sternir.com
Media Contact:Amy PhillipsGreen
Room CommunicationsDirect:
412-327-9499aphillips@greenroompr.com
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
EyePoint Pharmaceuticals (NASDAQ:EYPT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024